Table 4.
Comparison of the clinical, laboratory, and functional parameters at the baseline and 12th and 24th weeks.
| N=15 | Premepolizumab | Mepolizumab12th Week | P* | Mepolizumab24th Week | P** |
| Methylprednisolone equivalentsystemic steroid dose, mg, mean ± SD | 9.2±5.2 | 2.8±2.2 | <0.001 | 1.3±1.4 | <0.001 |
| Number of asthma exacerbationsin the last 24 weeks, mean ± SD | 2.1 ± 2.7 | 0.07 ± 0.26 | - | 0.07 ± 0.26 | 0.012 |
| ACT mean ± SD | 18 ± 5.7 | 22.5 ± 3.6 | 0.011 | 23.3 ± 3 | 0.006 |
| Eos %, mean ± SD | 5.5 ± 5.8 | 1.3 ± 0.7 | 0.013 | 1.9 ± 1.4 | 0.029 |
| Eos count mean ± SD | 580 ± 607 | 106 ± 73 | 0.01 | 177 ± 137 | 0.019 |
| FEV1 %, mean ± SD | 80 ± 30.7 | 84 ± 26 | 0.342 | 84.6 ± 26 | 0.392 |
| FEV1 L/s, mean ± SD | 2092 ± 995 | 2156 ± 922 | 0.434 | 2232 ± 875 | 0.533 |
ACT: Asthma control test, eos: eosinophil. *Comparison of premepolizumab and mepolizumab, 12th week. **Comparison of premepolizumab and mepolizumab, 24th week.